International Registry of Thrombotic APS Patients Treated With Direct Oral Anticoagulants

Launched by STÉPHANE ZUILY · Feb 7, 2020

Keywords

ClinConnect Summary

**Summary of the Clinical Trial: International Registry of Thrombotic APS Patients Treated With Direct Oral Anticoagulants**

This clinical trial is setting up a registry to gather important information about patients with Antiphospholipid Syndrome (APS) who are being treated with direct oral anticoagulants (DOACs). APS is a condition that increases the risk of blood clots, and this study aims to ensure that data is collected consistently to understand the safety of these medications in patients who are not considered at high risk. By participating, patients will help researchers learn more about how well these treatments work and their potential side effects.

To be eligible for this study, participants must be at least 18 years old, have a confirmed diagnosis of APS, and have been on a DOAC for at least six months. Pregnant individuals and those under 18 cannot join. If you decide to participate, you will receive comprehensive information about the study and your health data will be monitored over time. This registry is important as it will help improve the understanding of APS treatment and enhance patient care in the future.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • Patient receiving a comprehensive information about the study, and not opposed to participate
• • Age ≥ 18 yo
• • Classification of definite APS according to revised Sapporo-Sydney criteria
• • Direct oral anticoagulant treatment prescribed during at least 6 months or with the possibility of follow-up of at least 6 months
• Exclusion Criteria:
• • Incomplete revised Sapporo-Sydney criteria
• • No data regarding the recurrent thrombosis
• • Pregnant woman
• • Age \< 18 yo